26.71
-0.62 (-2.27%)
| Penutupan Terdahulu | 27.33 |
| Buka | 27.45 |
| Jumlah Dagangan | 430,471 |
| Purata Dagangan (3B) | 1,115,963 |
| Modal Pasaran | 2,022,892,032 |
| Harga / Jualan (P/S) | 14.95 |
| Harga / Buku (P/B) | 6.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -121.73% |
| Margin Operasi (TTM) | -94.48% |
| EPS Cair (TTM) | -1.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 170.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.68% |
| Nisbah Semasa (MRQ) | 4.71 |
| Aliran Tunai Operasi (OCF TTM) | -75.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.20 M |
| Pulangan Atas Aset (ROA TTM) | -13.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -29.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Zymeworks Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.13 |
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.15% |
| % Dimiliki oleh Institusi | 102.76% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (B. Riley Securities, 49.76%) | Beli |
| 40.00 (Stifel, 49.76%) | Beli | |
| Median | 32.00 (19.81%) | |
| Rendah | 23.00 (JP Morgan, -13.89%) | Beli |
| Purata | 32.00 (19.81%) | |
| Jumlah | 5 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 22.64 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citizens | 03 Dec 2025 | 32.00 (19.81%) | Beli | 25.10 |
| B. Riley Securities | 21 Nov 2025 | 40.00 (49.76%) | Beli | 24.02 |
| 10 Oct 2025 | 30.00 (12.32%) | Beli | 18.06 | |
| Stifel | 19 Nov 2025 | 40.00 (49.76%) | Beli | 22.60 |
| Wells Fargo | 19 Nov 2025 | 25.00 (-6.40%) | Pegang | 22.60 |
| 07 Nov 2025 | 17.00 (-36.35%) | Pegang | 16.46 | |
| HC Wainwright & Co. | 18 Nov 2025 | 32.00 (19.81%) | Beli | 22.99 |
| 14 Oct 2025 | 26.00 (-2.66%) | Beli | 18.23 | |
| JP Morgan | 16 Oct 2025 | 23.00 (-13.89%) | Beli | 18.55 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |